Andrew Cowan, MD, Oncology, Seattle, WA, Seattle Cancer Care Alliance

AndrewJohnCowanMD

Oncology Seattle, WA

Hematologic Oncology

Assistant Professor, Medical Oncology at University of Washington; Assistant Member, Fred Hutchinson Cancer Research Center

Overview of Dr. Cowan

As an assistant professor of medicine in the Div. of Medical Oncology at the University of Washington School of Medicine, my focus is in plasma cell dyscrasias. I am involved in a variety of clinical research projects, both retrospective and prospective studies. I have a special interest in multiple myeloma and AL amyloidosis.

Before my fellowship, I was a Clinical Instructor at Boston Univ. School of Medicine. While at BU, I worked in Amyloidosis Center in the Div. of Hematology and Oncology as the 'amyloid internist,' a member of the multi-disciplinary team involved in the care of patients with amyloidosis. I also conducted clinical research in gastrointestinal amyloidosis and the impact of bone marrow amyloid deposits on stem cell mobilization and collection prior to autologous stem cell transplantation.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology/Oncology, 2012 - 2015
  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 2009 - 2011
  • Boston University Medical Center
    Boston University Medical CenterInternship, Internal Medicine, 2008 - 2009
  • University of Washington School of Medicine
    University of Washington School of MedicineClass of 2008

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2017 - 2021
  • MA State Medical License
    MA State Medical License 2011 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase
    Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
    Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...
    Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and More
    Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019

Grant Support

  • T32 Oncology Training GrantNIH2014–2015

Committees

  • Reviewer, Scientific Review Committee, FHCRC 2016 - Present

Professional Memberships

Hospital Affiliations